At the time of writing, Adma Biologics Inc [ADMA] stock is trading at $20.12, down -1.57%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADMA shares have gain 3.34% over the last week, with a monthly amount drifted -5.94%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Mizuho started tracking the stock with Buy rating on October 13, 2022, and set its price target to $5. On November 11, 2021, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $5 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $4.50 on November 09, 2021. Jefferies initiated its recommendation with a Buy and recommended $8 as its price target on June 04, 2019. H.C. Wainwright reiterated a Buy rating for this stock on April 15, 2019, and upped its price target to $13.
For the past year, the stock price of Adma Biologics Inc fluctuated between $9.31 and $25.67. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Adma Biologics Inc [NASDAQ: ADMA] shares were valued at $20.12 at the most recent close of the market. An investor can expect a potential drop of -20.48% based on the average ADMA price forecast.
Analyzing the ADMA fundamentals
According to Adma Biologics Inc [NASDAQ:ADMA], the company’s sales were 459.38M for trailing twelve months, which represents an 40.22% jump. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at 0.33%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.45%. To continue investigating profitability, this company’s Return on Assets is posted at 0.4, Equity is 0.72 and Total Capital is 0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Adma Biologics Inc [NASDAQ:ADMA] has a current ratio of 6.58. Further, the Quick Ratio stands at 3.36, while the Cash Ratio is 1.34. Considering the valuation of this stock, the price to sales ratio is 10.46, the price to book ratio is 12.85 and price to earnings (TTM) ratio is 23.84.
Transactions by insiders
Recent insider trading involved Guiheen Lawrence P., Director, that happened on May 21 ’25 when 9000.0 shares were purchased. President and CEO, Grossman Adam S completed a deal on May 15 ’25 to sell 21000.0 shares. Meanwhile, President and CEO Grossman Adam S sold 21000.0 shares on Apr 15 ’25.
